The company carries effectively no debt, with a debt-to-equity ratio of 0.00 and a current ratio of 43.55 in 2026Q3, though total assets have contracted from $144.2M in 2025Q3 to $130.2M as cash has been consumed.
Monopar Therapeutics Inc. (MNPR) balance sheet — 11-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 |
|---|
| Total Current Assets | 129.88M | 140.46M | 60.29M | 7.33M | 13.17M | 20.52M | 16.8M | 13.23M | 7.32M | 9.13M | 2.1M | 2.03M |
| Cash & Short-Term Investments | 129.45M | 140.4M | 60.21M | 7.27M | 13.12M | 20.3M | 16.74M | 13.21M | 6.89M | 8.98M | 2.07M | 2.01M |
| Cash Only | 52.63M | 61.83M | 45.82M | 7.27M | 8.19M | 20.3M | 16.74M | 13.21M | 6.89M | 8.98M | 2.07M | 2.01M |
| Short-Term Investments | 76.81M | 78.57M | 14.4M | 0 | 4.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 434.87K | 63.74K | 78.87K | 66.43K | 45.98K | 217.75K | 62.69K | 15.71K | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 366.72K | 254.92K | 0 | 12.65K | 61.23K | 0 | 68.86K | 122.38K | 410.67K | 800.03K | 800.39K | 800K |
| Property, Plant & Equipment | 366.72K | 254.92K | 0 | 12.65K | 61.23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 730.65M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 800.39K | 800K |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 68.86K | 122.38K | 410.67K | -729.85M | 0 | 0 |
| Total Assets | 130.25M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M | 16.87M | 13.35M | 7.32M | 9.93M | 2.9M | 2.83M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 424.8% | 133.4% | 720.83% | -44.47% | -35.55% | 21.66% | 26.34% | 82.46% | -26.31% | 242.98% | 2.39% | - |
| Total Current Liabilities | 2.98M | 2.74M | 5.25M | 1.76M | 3.13M | 1.58M | 1.18M | 724.16K | 399.55K | 311.87K | 64.51K | 73.84K |
| Accounts Payable | 2.82M | 2.74M | 2.25M | 1.76M | 3.13M | 1.58M | 1.18M | 724.16K | 399.55K | 311.87K | 64.51K | 73.84K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 43.55x | 51.35x | 11.47x | 4.17x | 4.21x | 12.98x | 14.28x | 18.27x | 18.32x | 29.28x | 32.48x | 27.46x |
| Quick Ratio | 43.55x | 51.35x | 11.47x | 4.17x | 4.21x | 12.98x | 14.28x | 18.27x | 18.32x | 29.28x | 32.48x | 27.46x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 199.81K | 154.92K | 0 | 0 | 8.41K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 594.12K | 154.92K | 0 | 0 | 8.41K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.18M | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M | 1.18M | 724.16K | 399.55K | 311.87K | 64.51K | 73.84K |
| Total Debt | 357.26K | 154.92K | 0 | 0 | 8.41K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -52.28M | -61.68M | -45.82M | -7.27M | -8.18M | -20.3M | -16.74M | -13.21M | -6.89M | -8.98M | -2.07M | -2.01M |
| Debt / Equity | 0.00x | 0.00x | - | - | 0.00x | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.54x | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | -32.27x | -343.07x | -163.83x | - |
| Total Equity | 127.07M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M | 15.69M | 12.63M | 6.92M | 9.62M | 2.83M | 2.75M |
| Equity Growth % | 443.5% | 150.43% | 884.95% | -44.62% | -46.73% | 20.71% | 24.26% | 82.53% | -28.08% | 239.78% | 2.79% | - |
| Book Value per Share | 14.84 | 18.60 | 4.79 | 0.39 | 0.79 | 1.52 | 1.43 | 1.19 | 0.66 | 0.92 | 0.29 | 0.34 |
| Total Shareholders' Equity | 127.07M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M | 15.69M | 12.63M | 6.92M | 9.62M | 2.83M | 2.75M |
| Common Stock | 6.76K | 6.69K | 6.1K | 14.9K | 12.95K | 12.6K | 11.45K | 10.59K | 9.29K | 9.29K | 0 | 0 |
| Retained Earnings | -104.91M | -89.51M | -75.79M | -60.21M | -51.8M | -41.29M | -32.19M | -25.88M | -21.66M | -18.43M | -1.87M | -687.31K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 95.23K | 131.39K | 35.99K | -14.13K | 8.94K | -3.16K | -7.87K | -10.97K | -2.4K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MNPR stock.
As of 2025, Monopar Therapeutics Inc. (MNPR) had total assets of $140.7M including $140.5M in current assets.
Monopar Therapeutics Inc. (MNPR) carries total debt of $0.2M, offset by $140.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Monopar Therapeutics Inc. (MNPR) has total shareholders' equity (book value) of $137.8M ($18.60 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Monopar Therapeutics Inc. (MNPR) reported a current ratio of 51.35x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Finite cash runway dependent on equity
Metrics are mathematically derived from official filings.
Cash-Funded Balance Sheet Expansion Reverses
According to reported quarterly balance sheets, MNPR's total assets rose from $53.9M in 2025Q2 to $144.2M in 2025Q3 before easing to $130.2M by 2026Q3, with equity tracking the same pattern and retained earnings deepening to -$104.9M.
The jump in assets during the second half of 2025 appears to reflect a capital raise rather than operating performance, since cash moved from $39.5M to $127.7M while liabilities remained modest. Since then, the balance sheet has been shrinking, with cash falling back to $52.6M, which suggests the company is consuming its funding faster than it is replenishing it. The steadily widening accumulated deficit confirms the trend is driven by sustained losses rather than any structural improvement in business quality.
Debt-Free Structure Limits Financing Options
Based on EDBL-style reported figures, MNPR carries effectively no debt, with total debt at $357.3K in 2026Q3 against equity of $127.1M, producing a debt-to-equity ratio of 0.00.
The absence of meaningful borrowing reduces refinancing and covenant risk, which is a genuine strength for a pre-revenue company without cash flow to service interest. However, the lack of debt also means the company has no leverage capacity to bridge funding gaps, leaving equity issuance as the realistic source of future capital. Investors should monitor how this dilution dependence interacts with the ongoing negative free cash flow.
Current Ratio Masks Shrinking Cash Cushion
As reported in the financial statements, MNPR's current ratio stands at 43.55 in 2026Q3, yet cash has declined from $61.8M at the end of 2025 to $52.6M, against quarterly operating cash burn of roughly $6M.
The very high current ratio reflects minimal current liabilities rather than a deep reservoir of liquid assets, so it overstates true financial flexibility. At the reported burn rate, the remaining cash implies a runway of roughly eight to nine quarters before additional capital is needed, though this estimate is sensitive to trial spending changes. The liquidity position is adequate in the near term but warrants close monitoring as the clinical programs advance.
Equity Base Eroded by Accumulated Losses
Based on reported equity figures, MNPR's shareholders' equity fell from $141.6M in 2025Q3 to $127.1M in 2026Q3, while retained earnings deteriorated from -$84.3M to -$104.9M over the same period.
The equity base is being drawn down almost entirely by operating losses, with no offsetting retained profits or revenue generation. The small buyback recorded in 2026Q1 is immaterial relative to the equity base and does not signal meaningful capital return. Equity quality therefore depends on the company's ability to raise future capital at acceptable prices to fund the pipeline.
Asset Quality Limited by Data Gaps
Based on the supplied balance sheet series, the headline asset base is dominated by cash, with goodwill and deferred revenue both reported at zero, but several quarterly figures show abrupt swings that may warrant further verification.
The sharp move in total assets between 2025Q2 and 2025Q3 is larger than the operating loss would explain, so the composition of that increase should be verified against the underlying filings. Because the company reports no goodwill and no deferred revenue, the balance sheet carries little impairment or forward-visibility risk, which keeps the analysis focused on cash burn. Investors should treat the cash balance as the critical asset and monitor it closely.